Prevalence, Severity, Concomitant Factors, and Natural Trajectory of Insomnia in Patients with Long COVID.

Prevalence, Severity, Concomitant Factors, and Natural Trajectory of Insomnia in Patients with Long COVID.

Publication date: Aug 29, 2025

Background/Objective: Insomnia is a clinically important symptom in Long COVID; however, few studies have addressed the presentation and course of insomnia symptoms in patients with Long COVID. Methods: The Insomnia Severity Index (ISI) was administered as part of a comprehensive baseline neuropsychological evaluation (Time 1) for patients with Long COVID at an Academic Medical Center (AMC). Data were gathered on 172 consecutively referred patients between the dates of November 2020 and May 2022. The mean age of patients at Time 1 was 49 years (range: 18 to 78), with a mean of 15 years of education. Patients were 70% female and 30% male and identified as White/Caucasian (78%), Black/African American (21%), or American Indian (1%). Patients’ severity of COVID-19 infection and self-reported emotional, somatic, cognitive, and fatigue symptoms were also gathered to identify concomitant risk factors for insomnia in Long COVID. Patients were then followed to observe the natural trajectory of insomnia complaints in Long COVID, with the Time 2 evaluation a mean of 9 months after the Time 1 evaluation. Results: Seventy-eight percent of Long COVID patients reported insomnia symptoms at Time 1, with 30% reporting Subthreshold Insomnia symptoms (ISI Score = 8-14), 30% reporting Moderate Insomnia symptoms (ISI Score = 15-21), and 18% reporting Severe Clinical Insomnia (ISI Score = 22-28). Severity of acute COVID-19 infection was not correlated with severity of insomnia in Long COVID; however, being non-white (r = 0. 24, n = 172, p

Open Access PDF

Concepts Keywords
African COVID-19
Caucasian Long COVID
Neuropsychological Long COVID insomnia
November mental health
Seventy

Semantics

Type Source Name
disease MESH Insomnia
disease MESH Long COVID
disease IDO symptom
disease MESH COVID-19
disease MESH infection
disease MESH anxiety
disease MESH depression
disease IDO intervention
disease MESH complications
disease MESH brain fog
disease MESH anxiety disorders
disease MESH suicide
disease MESH cognitive impairment
disease MESH post traumatic stress disorder
disease IDO history
disease IDO acute infection
disease MESH daytime sleepiness
drug DRUGBANK Methionine
drug DRUGBANK Coenzyme M
drug DRUGBANK Pentaerythritol tetranitrate
drug DRUGBANK Oxygen

Original Article

(Visited 6 times, 1 visits today)

Leave a Comment

Your email address will not be published. Required fields are marked *